NEWS & EVENTS

Inotrem announces €39 Million Series B Financing to Develop First- In-Class Immunology Therapeutics

Paris, September 12th. 2019. Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway with potential applications for acute and chronic inflammatory syndromes,announced today a €39 million Series B financing led by Morningside Ventures, joined byInvus with participation from existing investors Andera Partners, Sofinnova Partners and BiomedInvest.

Read full article – PDF

 

ut luctus sit elit. odio dolor. suscipit libero. justo id